Please sign in or register
Opt-out of cpdcentre.co.za website
PLEASE NOTE:
All your details stored on the site will be deleted. This is a permanent deletion of your data and as such we will not be able to reinstate your profile. You will however be given 1 calendar month to download all your certificates, from date of opt out, before the deletion of data runs.
🏅 Leaderboard Badges
-
The Pain Pioneer – Complete 3 CPD Trails in the Pain category
-
The Fever Fighter – Complete 3 CPD Trails in the Fever in Children category
-
Heartburn Hero – Complete 3 CPD Trails in the Reflux category
-
The Cardio Champion – Complete 3 CPD Trails in the Cardiovascular category
-
The Throat Titan – Complete 3 CPD Trails in the Sore Throat category
-
Clinical Educator – Complete 15 CPD Trails (across any category)
🎯 Earning Points
-
Visit the Virtual Classroom platform – 1 point per month
-
Complete a CPD Trail – 3 points
-
Watch a video or webinar – 1 point
-
Read and click “Confirm” for Virtual Classroom Content – 1 point
-
Pass a Virtual Academy Test – 1 point
Dear Healthcare Practitioner,
During this time of uncertainty, we would like to reassure our healthcare practitioners that we are here to support them in their efforts to combat COVID-19, and are focused on ensuring the health and well-being of all our customers and colleagues.
Due to the increased demand for your time and in the interest of health and safety for all, we have made available on the CPD Centre, a platform for detailing guides for you to consider in your own time.
By clicking the “Proceed” button, you confirm that you agree to be taken to our e-Detailing Platform, which details the brands and products of RB Healthcare.
References
TRANSACT
Flurbiprofen 40 mgReference: 1. Transact approved package insert. 27 May 1994.
STREPSILS
Flurbiprofen 8,75 mgReferences: 1. de Looze F, Russo M, Bloch M, Montgomery B, Shephard A, Smith G, et al. Efficacy of flurbiprofen 8.75 mg spray in patients with sore throat due to an upper respiratory tract infection: a randomised controlled trial. Eur J Gen Pract. 2016;22(2):111 -118. 2. Shephard A, Smith G, Aspley S, Schachtel BP. Randomised, double-blind, placebo-controlled studies on flurbiprofen 8.75 mg lozenges in patients with/without group A or C streptococcal throat infection, with an assessment of clinicians’ prediction of ‘strep throat’. Int J Clin Pract. 2015;69:59-71. 3. Turner R, Wevrett SR, Edmunds S, Brown MB, Atkinson R, Adegoke O, et al. Determination of the permeation and penetration of flurbiprofen into cadaveric human pharynx tissue. Clin Pharmacol. 2020:12:13 -20
GAVISCON
Flurbiprofen 8,75 mgReferences: 1. De Ruigh A, Roman S, Chen J, Pandolfino JE, Kahrilas PJ. Gaviscon Double Action Liquid (antacid & alginate) is more effective than antacid in controlling post-prandial oesophageal acid exposure in GERD patients: a double-blind crossover study. Aliment Pharmacol Ther. 2014;40(5):531-537.
NUROFEN
Ibuprofen 100 mg/5 ml & 200 mg/5 mlReferences: 1.Green RW, Webb D, Jeena PM, Wells M, Butt N, Hangoma JM, et al. Management of acute fever in children: Consensus recommendations for community and primary healthcare providers in sub-Saharan Africa. African Journal of Emergency Medicine 2021;11:283-296. 2. Marseglia G, Alessio M , Da Dalt L, Giuliano M, Ravelli A, Marchisio P. Acute pain management in children: a survey of Italian pediatricians. Ital J Pediatr 2019;45:156.
DISPRIN
100 mg AspirinReferences: 1. Sagar KA, Smyth MR. A comparative bioavailabilty study of different aspirin formulations using on-line multidimensional chromatography. Journal of Pharmaceutical and Biomedical Analysis 1999;21:383-392